Other psychostimulants and nootropics
ATC code: N06BX06 (Citicoline)
Brand names
Somazina, Ceraxon, NeurAxon
Citicoline (cytidine 5'-diphosphocholine, CDP-choline) is an intermediate in the biosynthesis of phosphatidylcholine, a major phospholipid of neuronal membranes. After oral or intravenous administration it is hydrolysed to cytidine and choline, which enter brain phospholipid metabolism. Proposed mechanisms include membrane phospholipid synthesis support, acetylcholine precursor supply and reduction of free fatty acid release after ischaemic injury. Citicoline is registered as a prescription drug in Russia, Spain, Italy, Japan and several Latin American countries, and is sold as a dietary supplement in the United States. The has not approved citicoline as a pharmaceutical product for any indication. Mechanism is plausible but downstream clinical translation has not been confirmed in adequately powered modern trials.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Citicoline is a neuroprotectant promoted for recovery after acute ischemic stroke. Trials have not shown convincing benefit for this use: it does not meaningfully change outcome or functional recovery. What actually helps in the acute phase is fast restoration of blood flow (thrombolysis and/or thrombectomy within the treatment window) plus care in a stroke unit. The substance itself is harmless here, but do not use it instead of treatment with proven benefit, or you lose time that effective treatment needs.
Standard therapy for acute ischemic stroke in international practice includes thrombolysis, thrombectomy, antiplatelets, and risk factor control. Citicoline is not part of evidence-based therapy.
Not recommended
Citicoline is a compound promoted to help restore memory and attention after a stroke. Studies have not shown convincing benefit for post-stroke cognitive impairment, and there is no solid evidence base for this use. What actually improves thinking and speech after a stroke is early neurorehabilitation – speech therapy, cognitive training, physical therapy – along with managing blood pressure, blood sugar and other risk factors for a repeat stroke. Citicoline is harmless in this role, but don't use it in place of rehabilitation and the proven treatment your doctor prescribes, or you risk missing the care that truly helps.
Not recommended
Citicoline is a compound promoted as a neuroprotectant for recovery after traumatic brain injury. Convincing benefit for this use has not been shown – there is no solid evidence that it improves outcomes. What actually makes a difference after TBI is timely care, monitoring, and rehabilitation guided by the treating team. Do not use citicoline in place of treatment with proven benefit, since that can mean missing care that truly helps.
Not recommended
Citicoline is marketed as a way to protect neurons and improve blood flow to the brain, including in vascular dementia. Clear benefit for this specific use has not been shown: there is no solid evidence that it changes cognition or the course of the disease. What actually helps in vascular dementia is managing risk factors – blood pressure, blood sugar, lipids – and working with a doctor on related conditions. Citicoline is harmless, but it should not replace treatment with proven benefit, or you may miss the care you need.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Not classified under the FDA system: not registered as a drug in the US. Russian local labels contraindicate use in pregnancy due to insufficient safety data.
Use during breastfeeding is contraindicated due to insufficient data on milk penetration and infant safety.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Citicoline is evaluated for the following indications with varying evidence strength: Post-stroke cognitive impairment (evidence tier D), Acute ischemic stroke (evidence tier D), Vascular dementia (evidence tier D). See the full indication matrix with dosing and citations above on this page.
Common side effects of Citicoline (≥ 1 in 100): Headache, Insomnia, Nausea, Decreased or increased blood pressure, Hot flushes. See the Safety section for uncommon and serious reactions.
FDA category C. Not classified under the FDA system: not registered as a drug in the US. Russian local labels contraindicate use in pregnancy due to insufficient safety data.
Use during breastfeeding is contraindicated due to insufficient data on milk penetration and infant safety.
Citicoline is contraindicated in: Hypersensitivity to citicoline; Severe parasympathetic hypertonia; Pregnancy – due to insufficient data; Breastfeeding – due to insufficient data; Age under 18 – due to insufficient data. Full list in the Safety section.
large RCTs (ICTUS 2012, over 2000 patients) and the Cochrane 2020 review showed no improvement in acute ischemic stroke outcomes versus placebo. Recovery comes from rehabilitation, not citicoline.
international guidelines (ESO 2023, AHA/ASA, AAN) do not include citicoline in standard care due to lack of evidence.
vascular dementia management relies on control of blood pressure, diabetes, dyslipidemia; unproven neuroprotectors do not replace this approach.
the COBRIT RCT (2012) showed no improvement in functional and cognitive recovery in TBI. Recovery comes from rehabilitation.